GlassScriptPhysician profile
Samit Patel
NPI 1427459163
$6,788.30
in general payments reported to CMS, 2019-2025
24 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 83% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $127 · 2021: $850 · 2022: $703 · 2023: $839 · 2024: $2,884 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Consulting Fee: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.99 |
| Consulting Fee | $1,156.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,511.75 | 2022-2025 | |
| Coloplast Corp | $807.98 | 2019-2025 | Peristeen, Speedicath |
| Abbvie INC. | $659.07 | 2019-2024 | |
| Neuraxis, INC. | $508.70 | 2024-2025 | |
| Mirum Pharmaceuticals, INC. | $314.25 | 2023-2025 | Livmarli |
| Qol Medical, LLC | $290.56 | 2021-2024 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $240.95 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $200.38 | 2021-2022 | |
| Phadia US INC. | $155.98 | 2021-2025 | Immunocap |
| Regeneron Healthcare Solutions, INC. | $131.52 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $122.30 | 2021 | |
| Medtronic Vascular, INC. | $120.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.73 | 2024-2025 | Gattex, Eohilia |
| Ipsen Biopharmaceuticals, INC | $97.49 | 2023-2024 | Bylvay, Iqirvo |
| Regeneron Pharmaceuticals, INC. | $97.39 | 2024 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $89.52 | 2024 | Ruconest |
| Alcresta Therapeutics, INC. | $74.57 | 2024 | Relizorb |
| Vivus LLC | $64.18 | 2022-2024 | Pancreaze |
| Rhythm Pharmaceuticals, INC. | $59.64 | 2022-2023 | Imcivree |
| Dentsply Ih Ab | $45.86 | 2024-2025 | Navina Rectal Catheter Set Regular |
| Travere Therapeutics, INC. | $24.92 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.94 | 2023 | Linzess |
| Mallinckrodt Hospital Products INC. | $23.65 | 2025 | Terlivaz |
| Acadia Pharmaceuticals INC | $21.42 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.